Cytokinetics, Incorporated announced five presentations related to aficamten at the upcoming European Society of Cardiology Congress 2025 in Madrid, highlighting positive topline results from the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. The Food and Drug Administration (FDA) has approved Camzyos ™ (mavacamten) for the treatment of adults with ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

When medications arent doing enough to manage your hypertrophic cardiomyopathy (HCM), surgical procedures can offer real relief. HCM is a genetic heart condition in which parts of the heart muscle ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Hypertrophic cardiomyopathy (HCM) is a long-term genetic condition that thickens the heart muscle and reduces blood flow. Early diagnosis can lower risks like sudden cardiac death, heart failure, and ...

MADRID -- The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...